Moderna vaccine trial pleases investors, EBITDAC backlash, Huawei sanctions

Moderna vaccine trial pleases investors, EBITDAC backlash, Huawei sanctions

By Financial Times

Positive results from the first US Covid-19 trial raised investors’ hopes of an economic rebound, Chinese self-driving car start-ups have been accelerating pilot projects as US rivals sit idle, and bond investors have hit out at the growing trend of companies reporting “earnings before coronavirus”. Plus, the FT’s Kiran Stacey explains what the latest US sanctions against Huawei mean for the Chinese telecoms company’s survival. 


To get free access to the FT’s Coronavirus Business Update newsletter for 30 days, visit ft.com/newsbriefingcovid or follow this link: https://www.ft.com/newsletter-signup/coronavirus?segmentId=9f398053-342f-c623-b5b3-1506d651696f.


Hosted on Acast. See acast.com/privacy for more information.


-
-
Heart UK
Mute/Un-mute